middle.news
Amplia lines up next narmafotinib trial with $25.6 million pro forma cash
8:22am on Wednesday 28th of October, 2026 AEDT
•
Biotechnology and Pharmaceuticals
Read Story
Amplia lines up next narmafotinib trial with $25.6 million pro forma cash
8:22am on Wednesday 28th of October, 2026 AEDT
Key Points
ACCENT pancreatic cancer trial nears completion with one patient still on study after 19 months
ACCENT data included a 36% overall response rate and 11.1-month median overall survival
ACCENT-MINI site start-up is under way, with ethics approval expected imminently
Eli Lilly collaboration will test narmafotinib with olomorasib in KRAS G12C lung cancer
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Amplia Therapeutics (ASX:ATX)
OPEN ARTICLE